Business
Abstract colorful wavy lines on blue background. Digital art print. Contemporary art and modern digital artwork concept.
Getty Images

A record 100 million Americans now pay for a music subscription — is streaming the final format for fans?

A brief look at the history of music suggests it might not be... as hard as that is to imagine.

The music business is still very much Streaming ft. Everything Else.

Just last week, Spotify announced that it paid the music industry $10 billion in royalties across 2024, in what the company said was the biggest annual payout from a single retailer in history. Now, new data from the Recording Industry Association of America (RIAA) shows that the relationship between streamers and the music business is very much a two-way street.

Last year, the average number of paid music subscriptions in America rose to a whopping 100 million as a record number of us cough up enough each month for on-demand access to our favorite songs through streaming services like Spotify or Apple Music (Apple). Naturally, those regular monthly payments translated to a massive chunk of the total cash that flowed through the recorded music industry in America last year, with total streaming revenues rising to $14.9 billion — roughly 84% of the industry’s top-line figure.

With this latest data from the RIAA confirming streaming’s current dominance, it’s hard to imagine a new format coming along and changing how we all listen to our favorite artists. But, if history is anything to go by, it's not entirely unlikely...

While audiophiles, nostalgia fiends, and (increasingly) Taylor Swift fans sent vinyl sales to a 36-year high of $1.4 billion, streaming is still the only real powerhouse format in the industry, as convenience continues to outweigh audio quality, aesthetics, and the tactile joy of owning physical things for most people in the US. 

Zooming out, the RIAA data shows that, when adjusted for inflation, recorded music industry revenues in the US are down 36% from their $27.5 billion peak in 1999, when we were all rushing out to buy albums from Britney Spears and Backstreet Boys on CD.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.